ANN ARBOR, Mich., March 17 /PRNewswire/ -- NanoBio Corporation reported top-level findings today from its phase 2b study of NB-001, a topical lotion to treat herpes labialis (cold sores). The ...

Lysine's precise role in the prevention and treatment of herpes labialis outbreaks is unknown. Of seven randomized, double-blind, placebo-controlled studies reviewed, six showed lysine to be effective ...

Second BioAlliance Pharma drug registered in the US An effective and innovative medicine for the treatment of a frequent infection, recurrent Herpes labialis in adults Paris, April 15, 2013 – ...

With consumers considering nutraceuticals as a means to fortify their daily dietary intake as well as an alternative to over-the-counter and prescription drugs, the outlook for the global ...

In a nested randomized controlled trial (RCT) published in eClinicalMedicine, researchers examined the effect of Bacillus Calmette-Guérin (BCG) vaccination on attenuating herpes labialis (cold sore) ...

This is a preview. Log in through your library . Abstract Background. Multiple studies of the use of acyclovir for the treatment of herpes labialis have suggested that the nominal efficacy of the ...

ST. PAUL, Minn., Aug. 5, 2019 /PRNewswire/ -- Squarex, a clinical-stage pharmaceutical company developing a topical immunomodulator for the long-term prevention of recurrent cold sores and other ...

Herpes simplex labialis (HSL) is a common disease caused most often by herpes simplex virus type 1 (HSV-1). Primary infection is usually acquired during childhood or adolescence through direct mucosal ...

CHARLESTON, S.C., July 21, 2014 /PRNewswire/ -- Innocutis is pleased to announce the introduction into the North American markets of Sitavig® (ACYCLOVIR) 50mg Buccal Tablet. Sitavig® (ACYCLOVIR) 50mg ...

The lips of 196 patients with a history of sun-induced herpes labialis were exposed to experimental ultraviolet radiation (UVR) and treated with acyclovir (ACV) or placebo at different times and by ...

Squarex Pharmaceutical Corporation has filed to raise capital via a U.S. IPO. The firm is developing a treatment for herpes simplex viral infections. SQRX is still a tiny company that is thinly ...